I t is now well established that systemic lupus erythematosus (SLE) 3 is under some form of polygenic control, in which several genetic factors independently contribute to the overall susceptibility and progression of the disease (1, 2) . Studies in several murine models of SLE suggest that heterogeneous combinations of multiple disease-associated genes apparently operate in a threshold manner to generate the disease (3) (4) (5) . Among such genetic factors, genes encoded within or closely linked to the MHC have been shown to be important for the development of the disease. Although it has not yet been determined how certain MHC alleles regulate the development of lupus-like autoimmune syndrome, it has been clearly shown that lupus susceptibility is more closely linked to the I-E Ϫ H-2 b haplotype than to the I-E ϩ H-2 d and H-2 k haplotypes in BXSB, (NZB ϫ BXSB)F 1 , and C57BL/ 6-lpr/lpr mice (6 -9) . Recently we have shown that the development of SLE is almost completely prevented in BXSB (I-E Ϫ , H-2 b ) mice expressing a transgene, Ea d , encoding the I-E d ␣-chain, which restores the I-E expression at the homozygous level (8, 10) . This strongly suggests that the reduced susceptibility associated with the I-E ϩ H-2 d and H-2 k haplotypes (vs the I-E Ϫ H-2 b ) can be related to the expression of the Ea gene, which is absent in the H-2 b mice because of the deletion of the promoter region of the Ea gene (11) .
Studies on lupus-prone mice expressing different levels of the Ea d transgene revealed that the protection conferred by the transgene is dependent on its level of expression, but not on that of whole I-E molecules on the surface of B cells (12, 13) . In addition, it has been observed that the level of protection markedly differs among lupus-prone mice studied: the highest in BXSB, intermediate in (MRL ϫ BXSB)F 1 , and the lowest in (NZB ϫ BXSB)F 1 and (NZW ϫ BXSB)F 1 mice (10, 12, 13) . This indicates that the disease-suppressing effect of the Ea d transgene is likely influenced by the presence or absence of specific disease-associated alleles present in different lupus-prone strains. Although the precise mechanisms responsible for the Ea d transgene-mediated protection of SLE have not yet been defined, the demonstration that autoantibodies were selectively produced by nontransgenic B cells in transgenic and nontransgenic double bone marrow chimeras indicated that B cells, and not T cells, are the major site of the transgene effect on the suppression of autoimmune responses (10, 14) . Thus, we postulated that Ea d transgene expression may lead to interference with an efficient interaction between autoreactive T and B cells by modulating the presentation of pathogenic selfpeptides by MHC class II molecules; this can result from increased formation of I-E ␣-chain-derived peptides (E␣ peptides) displaying a high affinity to the I-A molecules or from the induction or enhanced expression of mixed-haplotype I-E molecules (10, 12, 13) . If this is indeed the case, the protective ability of the Ea d transgene can be markedly influenced by the host H-2 haplotype because of variabilities in the binding affinity of individual MHC class II molecules to E␣ peptides and in the expression level of potential autoimmune-inhibitory mixed-haplotype I-E molecules in the transgenic mice bearing different H-2 haplotypes.
Due to the potential importance of this thesis, we generated (NZB ϫ BXSB)F 1 hybrids bearing the H-2 b/b , H-2 d/b , or H-2 d/d haplotype and (MRL ϫ BXSB)F 1 hybrids bearing the H-2 k/b or H-2 k/k haplotype, and compared the level of the Ea d transgenemediated protection from autoimmune manifestations (autoantibody production and glomerulonephritis) in relation to the host H-2 haplotype. We report in this paper that the autoimmune inhibitory effect of the Ea d transgene is dependent on the H-2 haplotype, suggesting that the action of the Ea d transgene is mediated through interaction with the host MHC class II molecules.
Materials and Methods
Mice A BXSB Ea d transgenic line, BXSB-E-1, which expresses the transgene at a high level, was established as previously described (10) . BXSB.H-2 d , BXSB.H-2 k , and NZB.H-2 b congenic mice, created by backcross procedures at the 12th, 12th, and 10th generations, respectively, were described (6, 8, 15) . NZB and MRL mice were purchased from Bomholtgard (Ry, Denmark). (NZB ϫ BXSB)F 1 and (MRL ϫ BXSB)F 1 mice were generated by local breeding. The presence of the transgene in F 1 offsprings was screened by Southern blot analysis, as described previously (10, 12) . A total of 15-30 mice were serially followed for serology, and when animals were moribund, complete autopsy was performed to establish the mortality rate due to glomerulonephritis. Mice were bled from the retroorbital plexus and resulting sera were kept at Ϫ20°C until use.
Serological assays
Serum levels of IgG anti-DNA autoantibodies were determined by ELISA, and results are expressed in titration units, as described previously (16) . Serum levels of gp70-anti-gp70 immune complexes (gp70 IC) were quantified by an ELISA combined with the precipitation of sera with polyethylene glycol (average m.w. 6000), and results are expressed as g/ml of gp70 complexed with anti-gp70 Abs, as described previously (6) .
Histopathology
Samples of all major organs were obtained at autopsy, and histological sections were stained with either the periodic acid-Schiff reagent or with hematoxylin and eosin. Glomerulonephritis was scored on a 0-to-4 scale, in blind, based on the intensity and extent of histological changes, as described (17) , according to Pirani and Salinas-Madrigal (18) . Grades 3 and 4 glomerulonephritis were considered significant contributors to clinical disease and/or death.
Cytofluorometric analysis
The expression of I-E molecules in peripheral blood B cells was analyzed by first staining them with FITC-conjugated anti-mouse chain (LO-MM-9) mAb (19) , and then by incubation with biotinylated anti-E␣ (H81.98.21.1) (20) or anti-E␣ d E␤ b (Y-17) (21) mAb, and then with PE-conjugated streptavidin (Caltag Laboratories, San Francisco, CA). Lastly, they were analyzed with FACScan (Becton Dickinson, Mountain View, CA).
Statistical analysis
Survival curves were estimated with BMDP statistical software (22) and compared using the Breslow statistic (23). Statistical analysis for serological parameters was performed with the Wilcoxon two-sample test. Probability values Ͼ5% were considered insignificant.
Results

H-2 haplotype-dependent protection of SLE by the Ea d transgene in (NZB ϫ BXSB)F 1 mice
To assess the role of the H-2 haplotype on the Ea d transgenemediated protection of SLE, (NZB ϫ BXSB)F 1 hybrids bearing different H-2 haplotypes (H-2 b/b , H-2 d/b , or H-2 d/d ) with or without the transgene were generated, and the effect of the transgene on the clinical development of SLE was assessed in these F 1 female mice. (NZB ϫ BXSB)F 1 nontransgenic females of H-2 b/b , H-2 d/b , and H-2 d/d haplotypes developed typical SLE; 50% of them died of glomerulonephritis by 7, 9, and 15 mo, respectively ( Fig. 1 ). Although the high-level expression of the transgene was very effective in the protection from SLE occurring in both H-2 b/b and H-2 d/b F 1 females, the protective effect of the Ea d transgene was far stronger in the H-2 b/b F 1 females ( Fig. 1 ). In fact, two-thirds of the H-2 b/b F 1 females bearing the transgene were still alive at 18 mo of age, whereas 50% of the H-2 d/b F 1 female transgenics died of glomerulonephritis by 17 mo of age ( p Ͻ 0.001). Most strikingly, the expression of the transgene barely altered the survival rate of the H-2 d/d F 1 females ( p Ͼ 0.1; Fig. 1 ).
The extent of the transgene-mediated prolongation of the lifespan observed among these three F 1 females bearing different H-2 haplotypes correlated well with the level of suppression of spontaneous autoantibody production, as determined by serum levels of IgG anti-DNA autoantibodies and gp70 IC (Table I) . Both autoantibody responses were nearly completely suppressed in the H-2 b/b F 1 female transgenics at any age tested (4, 6, and 8 mo of age; p Ͻ 0.001), but the level of the suppression was significantly less in the H-2 d/b female transgenics, despite comparable development of these autoantibody responses in both H-2 d/b and H-2 d/b nontransgenics. Consistent with a marginal effect of the transgene on the survival rate in the H-2 d/d F 1 females, these mice exhibited small decreases in serum levels of gp70 IC at 6 and 8 mo of age ( p Ͻ 0.001) and of IgG anti-DNA autoantibodies at 8 mo of age ( p Ͻ 0.05).
Because the onset, progression, and level of autoimmune responses were not comparable among the three different (NZB ϫ BXSB)F 1 female hybrids, the comparative analysis of the transgene-mediated protective effect on their development of SLE may not be pertinent. Therefore, we conducted a similar analysis in their male counterparts, because all three F 1 hybrid males, independently of their H-2 haplotypes, uniformly developed a very rapid course of the disease as a result of the autoimmune accelerating effect of the Yaa (Y-linked autoimmune acceleration) mutation (7) . The transgene-induced disease-suppressing effect was relatively limited in the F 1 hybrid males compared with their female counterparts. Nevertheless, the transgene expression in F 1 hybrid males bearing the H-2 b/b haplotype led to the most remarkable reduction in serum levels of IgG anti-DNA autoantibodies and gp70 IC (Table II) , and significantly prolonged their survival rate (50% mortality rate due to glomerulonephritis: 8 mo in transgenics and 5 mo in nontransgenics) (Fig. 2) . In contrast, significant but relatively small decreases in serum levels of gp70 IC, but not of IgG anti-DNA autoantibodies, were noted in F 1 males bearing either the H-2 d/b or H-2 d/d haplotype, whose life-spans were barely extended by the presence of the transgene (50% mortality rate in H-2 d/b mice: 7 mo in transgenics and 6 mo in nontransgenics; 50% mortality rate in H-2 d/d mice: 8 mo in transgenics and 7 mo in nontransgenics).
It should be mentioned that circulating B cells from all three different transgenic mice expressed I-E molecules, as examined by surface staining using anti-E␣ (H81.98.21.1) mAb, at levels comparable to those found in nontransgenic H-2 d/d F 1 hybrid mice (Fig. 3A) . However, as expected, the surface density of a mixedhaplotype I-E molecule, E␣ d E␤ b , as recognized by the Y-17 mAb, was higher in the H-2 b/b transgenic F 1 hybrids than that of the H-2 d/b F 1 transgenics, although the latter mice expressed a higher level of the E␣ d E␤ b heterodimer than their nontransgenic H-2 d/b littermates did (Fig. 3B ). (24) . The transgene-induced suppression of a lupus-like syndrome was highly significant in both H-2 k/b and H-2 k/k (MRL ϫ BXSB)F 1 transgenic males (Fig. 4) . The 50% cumulative mortality rates of both transgenic F 1 male hybrids were 14 and 15.5 mo, respectively, compared with their nontransgenic male littermates (H-2 k/b , 5.5 mo; H-2 k/k , 8 mo). The greatly prolonged survival in the transgenic F 1 males was reflected most in serum levels of gp70 IC (Table III) . At 4 mo of age, serum gp70 IC concentrations in both H-2 k/b and H-2 k/k F 1 transgenic males were markedly reduced compared with those of nontransgenic F 1 male mice ( p Ͻ 0.001). A partial reduction in IgG anti-DNA levels was seen only in the H-2 k/b F 1 males ( p ϭ 0.01) and not in the H-2 k/k F 1 males ( p Ͼ 0.1). These results suggest that the protective capacity of the Ea d transgene may be more effective in the H-2 k/b F 1 males than in the H-2 k/k F 1 males. This was further supported by the analysis of their F 1 female hybrids, which develop a mild, but not lethal, form of lupus. The expression of the transgene reduced the production of IgG anti-DNA autoantibodies only in H-2 k/b (MRL ϫ BXSB)F 1 female hybrids ( p Ͻ 0.001), and not in H-2 k/k F 1 females ( p Ͼ 0.1) (Table III) . Although the H-2 k/k F 1 females developed low levels of gp70 IC detectable at 8 mo of age, its production was completely inhibited by the presence of the transgene ( p Ͻ 0.01), as is the case for the H-2 k/b F 1 females ( p Ͻ 0.001). Notably, the surface density of I-E molecules, as determined by staining with anti-E␣ mAb, on circulating B cells from these two different transgenic mice was comparable to that found in nontransgenic H-2 k/k F 1 hybrid mice (data not shown).
Discussion
In this study, we have investigated the specific contribution of select H-2 haplotypes on the Ea d transgene-mediated protection from SLE in (NZB ϫ BXSB)F 1 and (MRL ϫ BXSB)F 1 hybrid mice. We demonstrate that the level of the protection conferred by the transgene is highly dependent on the host H-2 haplotype. Although the molecular mechanism responsible for this H-2 association with the transgene-mediated protection remains to be defined, these results suggest that the autoimmune suppressive activity of the transgene is likely to be determined through the interaction of the transgene product with the host MHC class II molecules, thereby possibly modulating the presentation of pathogenic self-peptides by MHC class II molecules implicated in murine SLE.
The comparative analysis of (NZB ϫ BXSB)F 1 hybrid mice bearing three different H-2 haplotypes has demonstrated that the inhibitory effect of the Ea d transgene on clinical development of SLE (autoantibody production and glomerulonephritis) is the strongest with the H-2 b/b haplotype, intermediate with the H-2 d/b haplotype, and the weakest with the H-2 d/d haplotype (Table IV) . This strongly suggests that the disease-suppressing effect conferred by the transgene is determined by specific mechanism(s) linked to the host H-2 haplotype. This is consistent with the observation that the autoimmune-inhibitory effect mediated by the transgene is somehow more selective for anti-gp70 autoantibody than for anti-DNA Ab, as best shown in H-2 k/k (MRL ϫ BXSB)F 1 hybrid mice. All these data strongly argue against the idea that the prevention of SLE results from a nonspecific functional defect in B cells (and/or other APCs) secondary to overexpression of the transgene, as was the case in mice bearing a high-copy number of the Ab k transgene (25) . Instead, as discussed below, the action of the Ea d transgene may be more specifically involved in the process of autoimmune responses.
Additional analysis of (MRL ϫ BXSB)F 1 mice bearing either the H-2 k/b or H-2 k/k haplotype revealed that the H-2 k/k is also a sensitive haplotype for the disease-suppressing effect of the Ea d transgene. However, the (MRL ϫ BXSB)F 1 mice bearing the H-2 k/b haplotype were more susceptible to the transgene effect than those bearing the H-2 k/k haplotype because spontaneous production of IgG anti-DNA autoantibodies was suppressed only in the H-2 k/b hybrids but not at all in the H-2 k/k hybrids. Because the experiments were not conducted in mice bearing the same genetic background, direct comparison for the relative role the H-2 b and H-2 k haplotypes in the transgene-mediated protection was not possible. However, we and others observed that expression of the transgene consistently inhibited the production of IgG anti-DNA autoantibodies in BXSB, (NZB.H-2 b ϫ BXSB)F 1 , and C57BL/6lpr/lpr mice bearing the H-2 b haplotype (10, 14) . Therefore, the protective effect conferred by the Ea d transgene is likely to be more effective in mice with the H-2 b haplotype than in those with the H-2 k haplotype (Table IV) .
Our demonstration, a remarkable association of the Ea d transgene-mediated protective effect with the host H-2 haplotype, favors a model that the transgene expression in B cells may modulate the presentation of pathogenic self-peptides by MHC class II molecules (I-A and/or I-E), thereby interfering with an excessive activation of potential autoreactive T and B cells. We propose two possible mechanisms of modulation for autoantigen presentation as a result of either excessive generation of E␣ peptides with a high affinity to the I-A molecules, thereby decreasing the use of I-A molecules for presentation of pathogenic self-peptides, or the induction or increased production of unique mixed-haplotype I-E molecules, such as E␣ d E␤ b , which interfere with the presentation of pathogenic determinants by other MHC class II molecules as a consequence of capturing self-peptides (10, 12, 13, 26) . In this regard, it is important to note that the transgenic H-2 d mice express only a single type of I-E d molecule and not additional novel I-E molecules with different peptide-binding specificities (Table IV) . This likely is also the case in mice bearing the H-2 k haplotype. The transgenic H-2 k mice can produce a novel mixed-haplotype E␣ d E␤ k heterodimer (Table IV) ; however, its peptide-binding specificity should be identical with that of the conventional I-E k (E␣ k E␤ k ) molecule because a single amino acid difference localized at the junctional region between the ␣2 domain and the transmembrane domain between the extracellular region of the E␣ d and E␣ k chains cannot affect the peptide-binding specificity of these two I-E heterodimers (27) . Thus, a marked suppression observed in the H-2 k/k (MRL ϫ BXSB)F 1 transgenic mice supports the importance of the E␣ peptide-dependent mechanism for the inhibition of autoantibody production. In addition, the protection of the disease in the H-2 k/k transgenic mice, whose expression of I-E molecules does not quantitatively and qualitatively differ from nontransgenic littermates, further argues against the proposal that the transgene effect is a consequence of thymic selection of a harmful autoreactive T cell repertoire.
A relatively limited protection in the H-2 d/d transgenic mice expressing only the conventional I-E d molecules was unexpected because the I-A d molecule has been shown to have a high affinity to one of the E␣ peptides (28) . However, expression of the two endogenous Ea d genes in the H-2 d mice may be sufficient to inhibit the autoimmune responses mediated by I-A d molecules because the introduction of two copies of the Ea d transgene is able to almost completely prevent the development of SLE in BXSB (I-E Ϫ , H-2 b ) mice (8) , whose I-A b molecule also has a high affinity to the E␣ peptide, like the I-A d molecule (29) . If this is so, it can be speculated that I-E d molecules may be responsible for the development of relatively weak autoimmune responses occurring in the H-2 d/d F 1 hybrid mice and that these I-E d -dependent autoimmune responses can only be slightly suppressed, if at all, by the E␣ peptide-dependent mechanism, because of a possible limited affinity of the I-E d molecules to E␣ peptides. In contrast to the H-2 d and H-2 k mice, the H-2 b mice express only the mixed-haplotype E␣ d E␤ b heterodimer in the presence of the transgene (Table IV) , and its expression level is much higher than that seen in H-2 d/b and H-2 k/b heterozygous mice. If the E␣ d E␤ b heterodimer is indeed implicated in the autoimmune suppressive activity, the best protection observed in H-2 b mice can be explained by the additive effect of the E␣ peptide-mediated and E␣ d E␤ b mixed haplotypemediated inhibition of the presentation of pathogenic self-peptides by MHC class II molecules.
The present results indicate that the protective effect conferred by the Ea d transgene is likely to be much more complex than we thought initially, but support that the overall disease-suppressing effect of the Ea d transgene can be determined by several different factors. They include: 1) the affinity of individual MHC class II molecules to peptides derived from the transgene product, I-E ␣-chains (28 -30); 2) the expression level of potential autoimmune inhibitory mixed-haplotype I-E molecules generated in the transgenic mice; and 3) the relative contribution of individual MHC class II molecules to the development of autoimmune response characteristics of SLE. Accordingly, the interpretation for a better protection observed in H-2 d/b heterozygous (NZB ϫ BXSB)F 1 mice than H-2 d/d F 1 mice and in H-2 k/b (MRL ϫ BXSB)F 1 mice than H-2 k/k F 1 mice is complex because these H-2 heterozygous mice express multiple I-A and I-E molecules in which the precise contributions of each class II molecule to the development of SLE and whose affinities to E␣ peptides have been poorly defined. This would also explain why the introduction of the Ea z transgene in (C57BL ϫ NZB) ϫ NZB backcross mice has no effect on the development of autoantibody production (31).
In conclusion, our data indicate that the H-2 haplotype is an important genetic factor which controls the protective effect of the Ea d transgene. Because the expression of two copies of the Ea gene is capable of providing protection from SLE (8, 9, 32) , the possible role of the MHC class II Ea gene as a lupus-protective gene in mice is likely to be influenced by the host MHC haplotype. However, it should be stressed that the effect of the Ea d transgene can be modulated by genetic factors other than the MHC class II genes present in the genetic background of individual lupus-prone mice. This was best exemplified by the demonstration that the level of the protection conferred by the transgene is complete in H-2 b BXSB males (10) but only partial in H-2 b/b (NZB ϫ BXSB)F 1 male mice, as shown in this study. Furthermore, our present and previous studies also revealed that the protective effect of the transgene is counteracted by the presence of the Yaa gene in mice highly predisposed to SLE such as (NZB ϫ BXSB)F 1 and (NZW ϫ BXSB)F 1 mice. This observation is consistent with the thesis that the action of the Yaa gene may be implicated in the process of efficient interaction of autoreactive T and B cells (24, 33, 34) . Clearly, further understanding of the Ea d transgene-mediated protective mechanism and the Yaa gene-mediated accelerating mechanism would help elucidate the molecular and cellular basis central to the development of murine SLE.
